Over the last two decades it has spread across the world to more than 100 countries, causing regular outbreaks in Asia and Africa, massive outbreaks in the Americas, and more sporadic and clustered cases in Europe.Īs symptoms of chikungunya overlap with those of other mosquito-borne diseases, such as dengue and malaria, differential diagnosis in endemic areas is essential for optimized patient management. Transmitted to humans through the bites of infected mosquitoes, chikungunya virus (CHIKV) was first identified in Tanzania in 1952. bioMérieux is by your side from installation to integration to daily operations to help you get the most of your solution.For a fully integrated sepsis solution from blood culture with BACT/ALERT ® VIRTUO ®, identification with BIOFIRE ® Blood Culture Identification 2 panel & VITEK ® MS PRIME, AST with VITEK ® 2 and SPECIFIC REVEAL™ & data analysis with MYLA ®.Flexible solution with a modular design to fit any lab activity.Actionable results with MIC and susceptibility category S, I, RĪdding SPECIFIC REVEAL™ to your bioMérieux Sepsis Solution offers you the fastest route to fully actionable results and support therapy decisions for improved patient outcomes.Up to 23 antimicrobials in the European panel.Sensor color changes report growth monitored every 10 minutes, allowing the rapid phenotypic identification of growth or its absence and the associated Minimum Inhibitory Concentration (MIC) determination to be made. SPECIFIC REVEAL™ utilizes Small Molecule Sensors that detects the volatiles released by microorganisms as they grow to quantify antibiotic efficacy. Rapid & accurate results direct from blood culture The bioMérieux comprehensive Sepsis Solution, with the addition SPECIFIC REVEAL™, helps to manage your patient therapy all along the pathway bringing you rapid and reliable results to support clinical decisions for better patient care. Yet, if a patient initially receives inappropriate antimicrobial treatment, they are five times less likely to survive 3. If a patient receives antimicrobial therapy within the first hour of diagnosis, chances of survival are close to 80% this goes down by 7.6% for every hour after 2. Indeed, chances of survival go down drastically the longer initiation of treatment is delayed. Predicting antimicrobial resistance (AMR), can be more complex and time-intensive for patients with Gram negative infections.Įarly diagnosis and appropriate treatment make a critical difference when it comes to improving sepsis patient outcomes. SPECIFIC REVEAL™: THE NEW ADDITION TO THE BIOMÉRIEUX SEPSIS SOLUTION Sepsis management
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |